Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In the space of a few weeks, four articles appeared in the The Lancet and JAMA suggesting that using 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) is associated with increased bone mineral density (BMD) and a reduced fracture risk. The stimulus for these case-control studies came from reports that the statins have unexpected effects on bone, increasing bone formation in rodents. These observations offered a new insight into the potential importance of the cholesterol synthesis pathway in bone turnover and future therapeutic opportunities.

Original publication




Journal article


Calcif tissue int

Publication Date





63 - 66


Animals, Bone Density, Bone and Bones, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Mevalonic Acid